How ‘miracle’ weight-loss drugs will change the world (Nature)

In 2030, the transformative potential of weight-loss drugs, particularly GLP-1 agonists like semaglutide (Ozempic/Wegovy), could yield global health and economic benefits, from reduced heart attacks and healthcare costs to decreased fuel consumption in airlines due to lighter passengers. These drugs, already showing significant impacts in the U.S., could cut obesity-related health issues, boost productivity, and lessen economic disparities. However, uncertainties remain around the long-term effects, costs, and potential behavioral changes of users, raising questions about access, affordability, and the broader societal impact of GLP-1 drugs.